Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.81
9.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc
Revenue
Aurinia Pharmaceuticals Inc
Revenue Peer Comparison
TH
RPTX
COV
EDT
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Revenue
$207.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
238%
|
CAGR 10-Years
72%
|
|
B
|
Bright Minds Biosciences Inc
CNSX:DRUG
|
Revenue
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Theratechnologies Inc
TSX:TH
|
Revenue
$84.3m
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
33%
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Revenue
$51.1m
|
CAGR 3-Years
700%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Covalon Technologies Ltd
XTSX:COV
|
Revenue
CA$29.2m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
12%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Revenue
CA$1.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-4%
|
Aurinia Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Aurinia Pharmaceuticals Inc
|
Total Revenue:
175.5m
USD
|
|
United States:
158m
USD
|
|
Japan:
17.6m
USD
|
Breakdown by Segments
Aurinia Pharmaceuticals Inc
|
Total Revenue:
175.5m
USD
|
|
Product Revenue, Net:
158.5m
USD
|
|
License, Collaboration And Royalty Revenue:
17m
USD
|
See Also
What is Aurinia Pharmaceuticals Inc's Revenue?
Revenue
207.1m
USD
Based on the financial report for Jun 30, 2024, Aurinia Pharmaceuticals Inc's Revenue amounts to 207.1m USD.
What is Aurinia Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 10Y
72%
Over the last year, the Revenue growth was 29%. The average annual Revenue growth rates for Aurinia Pharmaceuticals Inc have been 53% over the past three years , 238% over the past five years , and 72% over the past ten years .
You don't have any saved screeners yet
